Killer Cells Articles & Analysis: Older
37 news found
CAR-T (chimeric antigen receptor T-cell) and CAR-NK (chimeric antigen receptor natural killer cell) therapies involve genetically modifying a patient's own immune cells to recognize and attack cancer cells more efficiently. By engineering these cells to express specific receptors on their ...
Partnered with the Dunbar CAR T-Cell Program at the University of Louisville as the GMP manufacturing center for INB-400. ...
DN-TNF is in clinical trials to determine if it can treat cancer (INB03™), Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with ...
European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural killer (NK) cells Patent portfolio broadly covers chemotherapy resistant engineering of innate immune cells for cellular therapy, providing the basis for ...
Fehniger, MD, PhD, Professor of Medicine, Washington University School of Medicine, an internationally recognized leader in natural killer (NK) cell immunotherapy, stem cell transplantation and lymphomas Prof. ...
Poster 159: Developing placental CD34+-derived natural killer cells with high affinity cleavage resistant CD16 (CYNK-101) and Cetuximab for enhanced therapy of EGFR+ non-small cell lung and head and neck cancers” Highlights: CYNK-101 is a cryopreserved off the shelf allogeneic NK cell product, overexpressing a high IgG ...
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, and TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem ...
“As we continue to advance clinical development of our pipeline, we believe our addition to the Russell indexes will broaden awareness of the biological advantages of placental-derived cell therapies, including both greater proliferative performance and natural immune tolerance. We remain committed to leading the next evolution of cellular therapies for the treatment of ...
(Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. ...
Yago Nieto, M.D., Ph.D., Professor of Stem Cell Transplantation and Cellular Therapy at MD Anderson, presented follow-up data to the investigator sponsored trial (IST) (AFM13-104) investigating the combination of AFM13 pre-complexed with cord blood-derived natural killer cells followed by AFM13 monotherapy in relapsed/refractory CD30+ lymphomas. ...
” The Trial in Progress posters provide background information and introduce the study designs of the three ongoing AFM24 studies in which patients with a variety of EGFR-positive solid tumors are treated with AFM24 monotherapy or in combinations with either Roche’s checkpoint inhibitor, atezolizumab, or NKGen Biotech’s autologous NK cell product, SNK01. ...
(Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,054,055 shares of its Class A common stock at a purchase price of $7.40 per ...
The presentations highlight new data related to the application of gene circuit technology to enhance efficacy and safety of cancer-killing allogeneic chimeric antigen receptor (CAR) natural killer (NK) cells. “This year's ASGCT presentations mark significant progress across our pipeline of allogeneic gene circuit-enabled CAR-NK cell ...
(CytoImmune), a clinical-stage immunotherapy company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies. G-CON PODs were built in College Station and have been shipped and integrated into CytoImmune’s custom-designed facility. ...
Ongoing Phase 1 study of unmodified placental-derived natural killer (NK) cell therapy candidate, CYNK-001, in acute myeloid leukemia (AML) continues enrolling new cohorts to reflect adjustments to treatment regimen and dosing as outlined in December 2021 Ongoing Phase 1 study of CYNK-001 in glioblastoma multiforme (GBM) U.S. ...
Correlative science data from AFM24-101 clinical study support the rationale to develop AFM24 as monotherapy and in combination therapies First preclinical data set on the combination of AFM28 with natural killer cells, both in co-administration or pre-complexed, demonstrates cytotoxic activity against CD123-positive tumor cells Heidelberg, ...
International Society for Cell and Gene Therapy (ISCT) Annual Meeting: May 4–7, 2022 in San Francisco, CA Process Development and Scale-Up for Gene Circuit Engineered CAR-NK Cell Manufacturing, Wood et al. ...
Senti Bio uses its Gene Circuit platform to program cell and gene therapies with potentially enhanced capabilities. Gene Circuits, which are created via synthetic biology and encoded as novel and proprietary combinations of DNA sequences, enable cells to sense inputs, compute decisions with biological logic, and respond to disease environments. ...
Preclinical data demonstrate the use of gene circuits to improve the therapeutic potential of allogeneic CAR-NK cells for the treatment of solid tumors CAR-NK cells armed with calibrated release IL-15 achieve optimal cytokine distribution and result in superior killing and persistence Senti Bio, a leading gene circuit company, today announced new data ...
The data demonstrate that CB-011 CAR-T cells are cytotoxic against BCMA-expressing tumor cells and are resistant to killing by both allogeneic T cells and natural killer (NK) cells. ...